TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Ying Cheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.